Loading…
Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer
Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects. The results for N-acetylation pharmacogenetics were against the initial expectation th...
Saved in:
Published in: | European journal of clinical pharmacology 1989-11, Vol.37 (6), p.581-587 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3 |
container_end_page | 587 |
container_issue | 6 |
container_start_page | 581 |
container_title | European journal of clinical pharmacology |
container_volume | 37 |
creator | HORAI, Y FUJITA, K ISHIZAKI, T |
description | Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects. The results for N-acetylation pharmacogenetics were against the initial expectation that there would be a preponderance of slow acetylators in the cancer group, as 3 such patients (5.9%) were found as compared to 13 (6.4%) in the healthy group. There was no poor metabolizer (PM) of metoprolol in the cancer group, whereas in the healthy group one (0.5%) was a PM. There were no significant differences between the groups in the frequency of slow acetylator and poor oxidiser phenotypes, or in the frequency distribution profiles of acetylation (monoacetyldapsone/dapsone) and oxidative metabolic ratio (log metoprolol/alpha-hydroxymetoprolol). The results indicate that neither N-acetylation nor the debrisoquine/sparteine-type oxidative phenotype and/or capacity represent a genetic predisposition to spontaneous bladder carcinogenesis in Japanese patients. In the normal Japanese population there is a great predominance of rapid acetylators and extensive oxidisers. |
doi_str_mv | 10.1007/BF00562549 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00562549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2612554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3</originalsourceid><addsrcrecordid>eNpFkDFPwzAQhS0EKqWwsCN5YEIK2E7sJiNUtIAqWLpHzvkijFInsl1BJ_46hlZluju97073HiGXnN1yxqZ3D3PGpBKyqI7ImBe5yDgr-DEZM5bzTFVTdkrOQvhgjMuK5SMyEooLKYsx-V6gw2hBd92WGozo19ahoa-ZBozbTkfbO6qdof2XNbsJ9KDBRouBWkdf0uQwIB2Sii4G-mnjO3W9y3qAzfC3ozu68dZpv6VNp41Bn644QH9OTlrdBbzY1wlZzR9Xs6ds-bZ4nt0vMxBCxUyVsmnbRpegUSkQaETRiEJVABUXjJWJSp1mU5hyyEUFlRSCJ5dcylLnE3KzOwu-D8FjWw_ertM7NWf1b4b1f4YJvtrBw6ZZozmg-9CSfr3XdUjBtT45seGAKVUozsv8B-QwemI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer</title><source>Springer Online Journal Archives (Through 1996)</source><creator>HORAI, Y ; FUJITA, K ; ISHIZAKI, T</creator><creatorcontrib>HORAI, Y ; FUJITA, K ; ISHIZAKI, T</creatorcontrib><description>Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects. The results for N-acetylation pharmacogenetics were against the initial expectation that there would be a preponderance of slow acetylators in the cancer group, as 3 such patients (5.9%) were found as compared to 13 (6.4%) in the healthy group. There was no poor metabolizer (PM) of metoprolol in the cancer group, whereas in the healthy group one (0.5%) was a PM. There were no significant differences between the groups in the frequency of slow acetylator and poor oxidiser phenotypes, or in the frequency distribution profiles of acetylation (monoacetyldapsone/dapsone) and oxidative metabolic ratio (log metoprolol/alpha-hydroxymetoprolol). The results indicate that neither N-acetylation nor the debrisoquine/sparteine-type oxidative phenotype and/or capacity represent a genetic predisposition to spontaneous bladder carcinogenesis in Japanese patients. In the normal Japanese population there is a great predominance of rapid acetylators and extensive oxidisers.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00562549</identifier><identifier>PMID: 2612554</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Acetylation ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Chi-Square Distribution ; Dapsone - analogs & derivatives ; Dapsone - blood ; Dapsone - metabolism ; Disease Susceptibility ; Female ; General pharmacology ; Humans ; Japan ; Male ; Medical sciences ; Metoprolol - analogs & derivatives ; Metoprolol - blood ; Metoprolol - metabolism ; Middle Aged ; Oxidation-Reduction ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Phenotype ; Urinary Bladder Neoplasms - epidemiology ; Urinary Bladder Neoplasms - genetics</subject><ispartof>European journal of clinical pharmacology, 1989-11, Vol.37 (6), p.581-587</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3</citedby><cites>FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6646118$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2612554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HORAI, Y</creatorcontrib><creatorcontrib>FUJITA, K</creatorcontrib><creatorcontrib>ISHIZAKI, T</creatorcontrib><title>Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects. The results for N-acetylation pharmacogenetics were against the initial expectation that there would be a preponderance of slow acetylators in the cancer group, as 3 such patients (5.9%) were found as compared to 13 (6.4%) in the healthy group. There was no poor metabolizer (PM) of metoprolol in the cancer group, whereas in the healthy group one (0.5%) was a PM. There were no significant differences between the groups in the frequency of slow acetylator and poor oxidiser phenotypes, or in the frequency distribution profiles of acetylation (monoacetyldapsone/dapsone) and oxidative metabolic ratio (log metoprolol/alpha-hydroxymetoprolol). The results indicate that neither N-acetylation nor the debrisoquine/sparteine-type oxidative phenotype and/or capacity represent a genetic predisposition to spontaneous bladder carcinogenesis in Japanese patients. In the normal Japanese population there is a great predominance of rapid acetylators and extensive oxidisers.</description><subject>Acetylation</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Chi-Square Distribution</subject><subject>Dapsone - analogs & derivatives</subject><subject>Dapsone - blood</subject><subject>Dapsone - metabolism</subject><subject>Disease Susceptibility</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Japan</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metoprolol - analogs & derivatives</subject><subject>Metoprolol - blood</subject><subject>Metoprolol - metabolism</subject><subject>Middle Aged</subject><subject>Oxidation-Reduction</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenotype</subject><subject>Urinary Bladder Neoplasms - epidemiology</subject><subject>Urinary Bladder Neoplasms - genetics</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNpFkDFPwzAQhS0EKqWwsCN5YEIK2E7sJiNUtIAqWLpHzvkijFInsl1BJ_46hlZluju97073HiGXnN1yxqZ3D3PGpBKyqI7ImBe5yDgr-DEZM5bzTFVTdkrOQvhgjMuK5SMyEooLKYsx-V6gw2hBd92WGozo19ahoa-ZBozbTkfbO6qdof2XNbsJ9KDBRouBWkdf0uQwIB2Sii4G-mnjO3W9y3qAzfC3ozu68dZpv6VNp41Bn644QH9OTlrdBbzY1wlZzR9Xs6ds-bZ4nt0vMxBCxUyVsmnbRpegUSkQaETRiEJVABUXjJWJSp1mU5hyyEUFlRSCJ5dcylLnE3KzOwu-D8FjWw_ertM7NWf1b4b1f4YJvtrBw6ZZozmg-9CSfr3XdUjBtT45seGAKVUozsv8B-QwemI</recordid><startdate>198911</startdate><enddate>198911</enddate><creator>HORAI, Y</creator><creator>FUJITA, K</creator><creator>ISHIZAKI, T</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198911</creationdate><title>Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer</title><author>HORAI, Y ; FUJITA, K ; ISHIZAKI, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Acetylation</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Chi-Square Distribution</topic><topic>Dapsone - analogs & derivatives</topic><topic>Dapsone - blood</topic><topic>Dapsone - metabolism</topic><topic>Disease Susceptibility</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Japan</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metoprolol - analogs & derivatives</topic><topic>Metoprolol - blood</topic><topic>Metoprolol - metabolism</topic><topic>Middle Aged</topic><topic>Oxidation-Reduction</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenotype</topic><topic>Urinary Bladder Neoplasms - epidemiology</topic><topic>Urinary Bladder Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HORAI, Y</creatorcontrib><creatorcontrib>FUJITA, K</creatorcontrib><creatorcontrib>ISHIZAKI, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HORAI, Y</au><au>FUJITA, K</au><au>ISHIZAKI, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1989-11</date><risdate>1989</risdate><volume>37</volume><issue>6</issue><spage>581</spage><epage>587</epage><pages>581-587</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects. The results for N-acetylation pharmacogenetics were against the initial expectation that there would be a preponderance of slow acetylators in the cancer group, as 3 such patients (5.9%) were found as compared to 13 (6.4%) in the healthy group. There was no poor metabolizer (PM) of metoprolol in the cancer group, whereas in the healthy group one (0.5%) was a PM. There were no significant differences between the groups in the frequency of slow acetylator and poor oxidiser phenotypes, or in the frequency distribution profiles of acetylation (monoacetyldapsone/dapsone) and oxidative metabolic ratio (log metoprolol/alpha-hydroxymetoprolol). The results indicate that neither N-acetylation nor the debrisoquine/sparteine-type oxidative phenotype and/or capacity represent a genetic predisposition to spontaneous bladder carcinogenesis in Japanese patients. In the normal Japanese population there is a great predominance of rapid acetylators and extensive oxidisers.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>2612554</pmid><doi>10.1007/BF00562549</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0031-6970 |
ispartof | European journal of clinical pharmacology, 1989-11, Vol.37 (6), p.581-587 |
issn | 0031-6970 1432-1041 |
language | eng |
recordid | cdi_crossref_primary_10_1007_BF00562549 |
source | Springer Online Journal Archives (Through 1996) |
subjects | Acetylation Adult Aged Aged, 80 and over Biological and medical sciences Chi-Square Distribution Dapsone - analogs & derivatives Dapsone - blood Dapsone - metabolism Disease Susceptibility Female General pharmacology Humans Japan Male Medical sciences Metoprolol - analogs & derivatives Metoprolol - blood Metoprolol - metabolism Middle Aged Oxidation-Reduction Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Phenotype Urinary Bladder Neoplasms - epidemiology Urinary Bladder Neoplasms - genetics |
title | Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetically%20determined%20N-acetylation%20and%20oxidation%20capacities%20in%20Japanese%20patients%20with%20non-occupational%20urinary%20bladder%20cancer&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=HORAI,%20Y&rft.date=1989-11&rft.volume=37&rft.issue=6&rft.spage=581&rft.epage=587&rft.pages=581-587&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00562549&rft_dat=%3Cpubmed_cross%3E2612554%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c226t-685bffba8cae66c2ed24b2469cc912008226c91a07c71c329c952216121558a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/2612554&rfr_iscdi=true |